SITE012-0169

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE012 (BRA) (Dr. Kowalski) · consented 2022-09-12

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 5); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 14); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 21); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 44); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-07 (study day 71); relationship: Y

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 79); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 101); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-21 (study day 147); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 151); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.